Financial Summary (All financials)
| In millions of CNY, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Mar-31-17 | Mar-31-16 | Mar-31-15 | Mar-31-14 |
| Revenues | 202.2 | 162.2 | 97.8 | 1.3 | 8.8 | 417.1 | 350.2 | 384.7 |
| Revenue growth | 24.7% | 65.9% | 7204.0% | | -97.9% | 19.1% | -9.0% | 4.9% |
| Cost of goods sold | 97.4 | 98.5 | 61.9 | 4.3 | 4.4 | 208.0 | 172.5 | 188.5 |
| Gross profit | 104.8 | 63.6 | 35.9 | -2.9 | 4.4 | 209.1 | 177.6 | 196.2 |
| Gross margin | 51.8% | 39.2% | 36.7% | -217.6% | 50.1% | 50.1% | 50.7% | 51.0% |
| Sales and marketing | 66.1 | 53.5 | 34.1 | 5.6 | 5.2 | 42.6 | 45.2 | 47.3 |
| Research and development | 11.8 | 8.8 | 11.8 | 19.6 | 19.9 | 36.5 | 36.8 | 27.7 |
| General and administrative | 93.3 | 100.1 | 81.9 | 43.5 | 36.1 | 78.3 | 64.8 | 71.6 |
| EBITA | -49.2 | -85.6 | -105.4 | -65.8 | -59.4 | 43.1 | 30.1 | 56.8 |
| EBITA margin | -24.3% | -52.8% | -107.8% | -4914.1% | -673.0% | 10.3% | 8.6% | 14.8% |
| Amortization of intangibles | 17.2 | 21.9 | 12.4 | 2.0 | 0.2 | 0.2 | 0.2 | 2.4 |
| EBIT | -66.4 | -107.5 | -117.8 | -67.8 | -59.6 | 42.9 | 29.9 | 54.5 |
| EBIT margin | -32.8% | -66.3% | -120.5% | -5064.4% | -675.3% | 10.3% | 8.5% | 14.2% |
| Pre-tax income | -37.9 | -110.9 | -141.3 | -68.1 | -58.2 | 45.0 | 32.6 | 47.2 |
| Income taxes | -1.5 | -10.3 | -7.1 | -923.0 | 1.5 | 18.9 | 9.6 | 19.9 |
| Tax rate | 4.1% | 9.3% | 5.1% | 1356.3% | | 42.1% | 29.3% | 42.2% |
| Earnings from continuing ops | -36.4 | -100.6 | -268.2 | -1,005.7 | -119.5 | 26.1 | 23.1 | 26.8 |
| Earnings from discontinued ops | | | 4.9 | 1,856.3 | 49.8 | | | |
| Net income | -36.4 | -100.6 | -263.3 | 850.6 | -69.7 | 26.1 | 23.1 | 26.8 |
| Net margin | -18.0% | -62.0% | -269.3% | 63544.5% | -789.3% | 6.2% | 6.6% | 7.0% |
| |
| Diluted EPS | ($0.58) | ($1.61) | ($5.27) | ($21.96) | ($2.61) | $0.57 | $0.51 | $0.59 |
| Shares outstanding (diluted) | 62.7 | 62.7 | 50.9 | 45.8 | 45.8 | 45.6 | 45.6 | 45.2 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|